In the follow-up study, a number of efficacy parameters will also be evaluated.
The study includes patients who do not respond satisfactory on hormonal therapy, which is given in order to inhibit the male hormone testosterone's stimulating effect on prostate cancer growth.
Patient recruitment has started and is expected to proceed during the beginning of 2005.
The study is carried out at the Urology clinics at the Sahlgrenska University Hospital
in Gothenburg and at the University Hospital in Lund.
Lund, December 13, 2004
Active Biotech AB (publ)
Sven Andréasson
President and CEO
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong research portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects involve unique substances with immunomodulatory properties (SAIK-MS) intended for the treatment of multiple sclerosis, as well as a novel concept for cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
www.activebiotech.com